The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

The chief commercial officer at Form Health advises benefit managers to take a close look at vendors and employee needs to ...

Starting Jan. 1, Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, will dramatically change how and when it pays for Zepbound— the insurer’ s preferred GLP-1 ...

Survey data suggest that less than half of employers with 500 or more workers cover GLP-1 medications for obesity. For small employers, coverage is less likely. In response to the frequent lack of ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges ... On the payer side, some companies are starting to exclude coverage ...

Here’s a glimpse of our latest GLP-1 trend data – discover how you can access the full dataset here. 1. Cost and insurance coverage are the top reasons consumers say they aren’t taking a GLP-1 drug.

CVS Caremark to list Wegovy as preferred GLP-1 drug on top formularies starting July 1, 2025. Novo Nordisk plans continued collaboration with CVS to widen Wegovy access. Unlock your all-in-one ...